Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Early COVID-19 treatment with drug combinations like fluvoxamine plus bromhexine significantly reduced clinical deterioration and viral load. These repurposed medications offer a promising, accessible option for managing SARS-CoV-2 infection.
Area Of Science
- Infectious Diseases
- Pharmacology
- Immunology
Background
- Repurposed drugs with antiviral and immunomodulatory properties show promise for COVID-19 treatment.
- Few trials have investigated combinations of these agents for SARS-CoV-2 infection.
- The study aimed to evaluate affordable, widely available repurposed drugs for COVID-19, particularly relevant for low-resource settings.
Purpose Of The Study
- To assess the effectiveness of drug combinations in preventing clinical deterioration in mild COVID-19 outpatients.
- To compare the efficacy of fluvoxamine alone, and in combination with bromhexine, cyproheptadine, or niclosamide, against standard care.
Main Methods
- An open-label, randomized, outpatient, controlled trial was conducted in Thailand.
- Adults with confirmed mild SARS-CoV-2 infection received early treatment (within 48 hours of symptom onset) with various drug combinations or standard care.
- The primary outcome was clinical deterioration within 28 days, assessed using a 6-point ordinal scale.
Main Results
- No clinical deterioration was observed by day 28 in participants treated with fluvoxamine plus bromhexine, fluvoxamine plus cyproheptadine, or niclosamide plus bromhexine.
- Combination therapies significantly reduced viral load, serum cytokines (IL-6, TNF-α, IL-1β, IL-8), and post-acute sequelae of COVID-19 (PASC) symptoms compared to standard care.
- Fewer serious adverse events were reported in combination treatment arms compared to standard care.
Conclusions
- Early treatment with repurposed drug combinations for COVID-19 significantly lowers the risk of clinical deterioration.
- These combinations rapidly reduce viral load and inflammatory markers, decreasing PASC symptom burden.
- Repurposed drug combinations represent a high-potential strategy to prevent COVID-19 progression and mortality.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...